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Progressive Left Ventricular Dysfunction and
Remodeling in Dogs With Heart Failure
Valerio Zacà, MD, Sharad Rastogi, MD, Makoto Imai, MD, Mengjun Wang, MD,
Victor G. Sharov, PHD, Alice Jiang, MD, Sidney Goldstein, MD, FACC,
Hani N. Sabbah, PHD, FACC
Detroit, Michigan
Objectives This study examined the effects of long-term monotherapy with rosuvastatin (RSV) on the progression of left ven-
tricular (LV) dysfunction and remodeling in dogs with heart failure (HF).
Background 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or “statins” possess other noncholesterol-lowering
properties that include inhibiting proinflammatory cytokines, attenuating LV hypertrophy, and stimulating the
release of bone marrow-derived stem cells (BMSCs).
Methods Twenty-one dogs with microembolization-induced HF were randomized to 3 months oral monotherapy with low-
dose (LD) RSV (0.5 mg/kg once daily, n  7), high-dose (HD) RSV (3.0 mg/kg once daily, n  7), or to no ther-
apy (control group, n  7). The change () from pre- to post-therapy (treatment effect) in LV end-diastolic vol-
ume (EDV) and end-systolic volume (ESV) and ejection fraction (EF) was measured. Protein level of tumor
necrosis factor (TNF)- in LV tissue and the number of circulating Sca-1–positive BMSCs was also determined.
Blood and LV tissue from 6 normal dogs was obtained and used for comparison.
Results There were no differences in EDV, ESV, and EF between control group and LD RSV. In contrast, EDV and
ESV were significantly lower, and EF was significantly higher in HD RSV compared with control group. High-
dose, but not LD, RSV also normalized protein levels of TNF- and was associated with a significant increase in
the number of circulating BMSCs.
Conclusions In dogs with HF, chronic therapy with HD RSV prevents progressive LV dysfunction and dilation. This benefit
may be partly derived from normalization of TNF- expression and partly from increased mobilization of
BMSCs. (J Am Coll Cardiol 2007;50:551–7) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.050n
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che 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
oA) reductase inhibitors, commonly referred to as statins,
odulate the activity of the enzyme that catalyzes the
ate-limiting step in cholesterol biosynthesis (1). In recent
ears, evidence from several large clinical trials has shown
hat statins reduce morbidity and mortality in patients with
irtually all stages of cardiovascular disease (CVD) (2). As a
esult, statins are currently recommended as a treatment of
hoice in the primary and secondary prevention of athero-
clerotic CVD (3).
rom the Department of Medicine, Division of Cardiovascular Medicine, Henry
ord Heart and Vascular Institute, Henry Ford Health System, Detroit, Michigan.
upported, in part, by research grants from AstraZeneca U.S. and the National Heart,
ung, and Blood Institute grant PO1 HL074237-04. All authors are full-time
mployees of Henry Ford Health System.s
Manuscript received November 27, 2006; revised manuscript received April 9,
007, accepted April 10, 2007.Statins have also been shown to possess a host of other
oncholesterol-lowering properties including ability to re-
uce systemic inflammation (4), improve endothelial func-
ion (5), stimulate angiogenesis (6), and mobilize bone
arrow-derived stem cells (BMSCs) (7–9), all of which can
ontribute to the improvement of left ventricular (LV)
unction and prevention or attenuation of progressive LV
emodeling in heart failure (HF). These properties consti-
ute a rationale for the chronic use of this class of drugs in
he prevention and treatment of HF. To date, only a few
xperimental (10–12) and observational (13–15) studies
ave reported a beneficial effect of statins in HF.
Rosuvastatin (RSV), a relatively new molecule, has
merged as an effective HMG-CoA reductase inhibitor
ith respect to lipid-lowering activity in low- to high-risk
atients, showing a safety and tolerability profile similar to
ommonly used doses of other statins (16). In the present
tudy, we investigated the effects of early long-term mono-
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Rosuvastatin in Heart Failure August 7, 2007:551–7therapy with RSV on LV function
and remodeling in dogs with in-
tracoronary microembolization-
induced HF.
Methods
Experimental model. The ca-
nine model of chronic HF used
in this study was previously de-
scribed in detail (17). In this
preparation, LV dysfunction is
produced by multiple intracoro-
nary microembolizations that re-
sult in loss of viable myocardium.
The model manifests many of
the sequelae of HF observed in
humans including marked and
progressive depression of LV sys-
tolic and diastolic function, re-
duced cardiac output, and in-
creased LV filling pressures. In
the present study, 21 healthy
mongrel dogs, weighing between
20 to 30 kg, underwent serial
coronary microembolizations to
produce HF. Embolizations
were performed 1 to 3 weeks
apart and were discontinued
when LV ejection fraction (EF),
determined angiographically,
was between 30% and 40%. All
the procedures were performed
during cardiac catheterization
under general anesthesia and
sterile conditions. Animals were
edated with intravenous oxymorphone hydrochloride (0.22
g/kg) and diazepam (0.17 mg/kg), and a plane of anes-
hesia was maintained with 1% to 2% isofluorane. The study
as approved by Henry Ford Health System Institutional
nimal Care and Use Committee and conformed to the
ational Institute of Health “Guide and Care for Use of
aboratory Animals” and the “Position of the American
eart Association on Research Animal Use.”
tudy protocol. Two weeks after the last embolization,
ogs underwent a prerandomization left and right cardiac
atheterization. One day later, dogs were randomized to 3
onths oral monotherapy with low-dose (LD) RSV (0.5
g/kg once daily, n 7), high-dose (HD) RSV (3.0 mg/kg
nce daily, n  7), or no therapy at all (control group,
 7). At the end of the follow-up period, a final left and
ight cardiac catheterization was performed. At the end of
he cardiac catheterization and while under general anes-
hesia, the chest was opened and the heart rapidly removed
or histological and biochemical examination. Whole blood
nd LV tissue were obtained from all HF dogs as well as
Abbreviations
and Acronyms
BMSC  bone marrow-
derived stem cell
CVD  cardiovascular
disease
ECM  extracellular matrix
EDV  end-diastolic volume
EF  ejection fraction
EPC  endothelial
progenitor cell
ESV  end-systolic volume
HD  high-dose
HF  heart failure
HMG-CoA  3-hydroxy-3-
methylglutaryl coenzyme A
LD  low-dose
LV  left
ventricular/ventricle
MCSA  myocyte cross-
sectional area
MI  myocardial infarction
MMP  matrix
metalloproteinase
ODD  oxygen diffusion
distance
RSV  rosuvastatin
TNF  tumor necrosis
factor
VFIF  volume fraction of
interstitial fibrosis
VFRF  volume fraction of
replacement fibrosisrom 6 normal dogs for comparisons with control and mSV-treated dogs. Blood samples were used to measure
otal cholesterol and triglyceride.
emodynamic and angiographic measurements. Hemo-
ynamic and angiographic measurements were made at
aseline, before any microembolization, at the time of
andomization, before initiation of therapy (pretreatment),
nd at the end of 3 months of therapy (post-treatment).
ortic and LV pressures were measured with catheter-tip
icromanometers (Millar Instruments, Houston, Texas).
eft ventriculograms were obtained with the dog placed on
ts right side and recorded on 35-mm cine film at 30 frame/s
uring the injection of 20 ml of contrast material (RENO-
-60, Squibb, Princeton, New Jersey). Correction for
mage magnification was made with a radiopaque calibrated
rid placed at the level of the LV. Left ventricular end-
ystolic volume (ESV) and end-diastolic volume (EDV)
ere calculated from LV silhouettes using the area-length
ethod, and EF was calculated as previously described (18).
troke volume was calculated as the difference between LV
DV and ESV. Cardiac output was calculated as the
roduct of stroke volume and heart rate. Extrasystolic and
ostextrasystolic beats were excluded from any analysis.
istomorphometric measurements. From each heart, in-
luding hearts from normal dogs, 3 transverse slices (ap-
roximately 3-mm thick), 1 each from basal, middle, and
pical thirds of the LV, were obtained. From each slice,
ransmural tissue blocks were obtained and embedded in
araffin blocks. Transmural tissue blocks were also obtained
rom the free wall segment of the slice, mounted on cork
sing Tissue-Tek embedding medium, and rapidly frozen in
sopentane precooled in liquid nitrogen and stored at
70oC until used. The volume fraction of replacement
brosis (VFRF); volume fraction of interstitial fibrosis
VFIF); myocyte cross-sectional area (MCSA), a measure of
ardiomyocyte hypertrophy; capillary density; and oxygen
iffusion distance (ODD) were measured as previously
escribed (19).
xpression of tumor necrosis factor- (TNF-), matrix
etalloproteinase (MMP)-2, and circulating BMSC
ounts. All tissue and blood samples were submitted for
nalysis without treatment regimen identifiers. Protein lev-
ls of TNF- and MMP-2 were measured in LV homog-
nate by Western blots. Primary antibodies specific to each
rotein were diluted based on the supplier’s instructions. In
ll instances, the antibody was present in excess over the
ntigen, and the density of each protein band was in the
inear scale. Band intensity was quantified in densitometric
nits. Circulating, Sca-1–positive BMSCs were isolated
rom whole blood. Sca-1–positive BMSC cells include
esenchymal, multipotent adult progenitor, and Hoechst
ide population cells (20). Samples were centrifuged over a
icoll-Hypaque gradient, and isolated cells were stained
ith primary and secondary antibodies containing immu-
ofluorescence (SC-8266, Santa Cruz Biotechnology, Inc.,
anta Cruz, California). Sca-1–positive BMSCs were
ounted using a hemocytometer coupled to fluorescent
icroscopy.
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August 7, 2007:551–7 Rosuvastatin in Heart Failuretatistical analysis. All angiographic and histomorpho-
etric analyses were performed in a blinded manner.
ntragroup comparisons of hemodynamic and angiographic
ariables for each of the 3 study groups were made between
easurements obtained just before initiation of therapy and
easurements made after completion of 3 months of
herapy. Student paired t test was used for comparisons of
retreatment versus post-treatment measures. To ensure
hat all study measures were similar at baseline before any
mbolizations and at the time of randomization before
nitiation of therapy (pretreatment), intergroup comparisons
ere made using a 1-way analysis of variance (ANOVA)
ith alpha set at 0.05. If the overall ANOVA was signifi-
ant, then pairwise comparisons were performed using the
tudent-Newman-Keuls test. To assess treatment effect, the
hange () in each measure from pretreatment to post-
reatment was calculated for each of the 3 study arms. To
etermine whether significant differences in  were present
etween the control group and each of the 2 treatment
roups, an ANOVA was performed with alpha set at 0.05.
f the overall ANOVA was significant, then pairwise com-
arisons were performed using the Student-Newman-Keuls
est. Histomorphometric results as well as protein expres-
ion results and BMSC counts obtained in all 3 study
roups and in a group of normal dogs were examined using
NOVA with alpha set at 0.05. If significance was attained
y overall ANOVA, pairwise comparisons were performed
sing the Student-Newman-Keuls test. For all pairwise
omparisons, a probability value 0.05 was considered
ignificant. All data are reported as the mean  SEM.
esults
ll 21 study animals survived the entire study. Baseline data
or all groups are shown in Table 1. Baseline hemodynamic
nd angiographic findings were within the normal range for
ongrel dogs in our laboratory. There were no significant
ifferences in any baseline parameters between control dogs
nd dogs randomized to either LD or HD RSV (Table 1).
imilarly, there were no significant differences between the
study groups in any of the parameters obtained at
Baseline Hemodynamic and Angiographic Measu
Table 1 Baseline Hemodynamic and Angiog
Control Group
(n  7)
HR (beats/min) 84 3.02
Mean AoP (mm Hg) 72 2.27
LV EDP (mm Hg) 10 1.13
SV (ml) 26 0.94
CO (l/min) 2.3 0.11
LV EDV (ml) 52 1.51
LV ESV (ml) 26 0.87
LV EF (%) 50 1.06
TC (mg/dl) 224 25
Trigl (mg/dl) 45 5
ANOVA analysis of variance; AoP aortic pressure; CO cardiac out
fraction; ESV  end-systolic volume; HR  heart rate; LV  left ventricular; R
Trigl  blood triglycerides.retreatment (Table 2). There were no significant differ-
nces in total cholesterol or triglycerides at any of the study
ime points (Tables 1 and 2).
emodynamic and angiographic findings. Three months
fter randomization, control dogs showed a significant
eterioration of LV EF accompanied by a significant
ncrease of LV EDV and LV ESV (Table 2). Similarly, 3
onths of therapy with LD RSV was associated with a
eduction of LV EF and an increase of both LV EDV and
SV. In dogs treated with HD RSV, LV EF increased
ignificantly whereas LV volumes remained essentially un-
hanged (Table 2). Heart rate, mean aortic pressure, and LV
nd-diastolic pressure remained essentially unchanged in all
study groups (Table 2). Stroke volume and cardiac output
id not change in control and LD RSV dogs, but increased
ignificantly in dogs randomized to HD RSV (Table 2).
omparisons of treatment effect. The changes () be-
ween pretreatment and post-treatment LV EF, EDV, and
SV are shown in Figure 1. Compared with that seen in
ontrol animals, HD RSV but not LD RSV prevented
rogressive LV dysfunction and dilation. High-dose RSV
ignificantly increased LV EF compared with that in control
ogs and LD RSV-treated dogs (Fig. 1). Both LV EDV
nd ESV were significantly smaller in the HD RSV group
han those seen in control or LD RSV groups (Fig. 1).
here were no significant differences in heart rate, mean
ortic pressure, and LV end-diastolic pressure among the 3
tudy groups. The change in stroke volume was not signif-
cantly different between control dogs (0.71  0.64) and
D RSV dogs (0.5 0.43) but was significantly higher in
D RSV dogs (1.43  0.3, p  0.011 vs. control group;
 0.003 vs. LD RSV). Similarly, the change in cardiac
utput did not differ between control group (0.13 0.09)
nd LD RSV group (0.03  0.04) but was significantly
igher in the HD RSV group (0.21  0.05, p  0.006 vs.
ontrol group; p  0.016 vs. LD RSV).
istomorphometric findings. Histomorphometric find-
ngs are shown in Table 3. Compared with that in normal
ogs, VFRF was significantly increased in control dogs.
here was a modest but insignificant decrease in VFRF in
Measures
ose RSV
 7)
High-Dose RSV
(n  7)
ANOVA
p Value
 2.27 80 2.27 0.524
 3.02 76 3.02 0.326
 0.76 11 1.13 0.731
 1.25 29 0.83 0.083
 0.15 2.4 0.4 0.608
 1.47 54 1.10 0.597
 1.32 25 1.13 0.467
 3.10 53 1.25 0.240
 14 207 15 0.802
 6 43 3 0.769
P end-diastolic pressure; EDV end-diastolic volume; EF ejectionres
raphic
Low-D
(n
83
71
11
26
2.2
53
27
48
210
48
put; ED
SV  rosuvastatin; SV  stroke volume; TC  total blood cholesterol;
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Rosuvastatin in Heart Failure August 7, 2007:551–7D and HD RSV dogs compared with that in control dogs.
olume fraction of interstitial fibrosis was significantly
igher in control dogs than that in normal dogs. The LD
SV had no effect on VFIF whereas HD RSV significantly
ecreased VFIF compared with that in control animals
Table 3). Compared with that in normal dogs, MCSA was
arger in control animals and decreased with both LD and
D RSV. In control dogs, capillary density was significantly
ower and ODD significantly longer compared with those in
ormal dogs. Treatment with LD RSV had no effect on
apillary density and ODD, whereas HD RSV tended to
ormalize both (Table 3).
ffects of RSV on TNF-, MMP-2, and BMSC. Com-
ared with those in normal dogs, LV protein levels of
NF- and MMP-2 were significantly increased in control
F dogs. High-dose RSV but not LD RSV normalized
rotein levels of TNF- and MMP-2 (Fig. 2). The number
f BMSCs was significantly reduced in control HF dogs
ompared with that in normal dogs (Fig. 3). High-dose
SV therapy was associated with a 3-fold increase in the
emodynamic and Angiographiceasures at Pre- and P st-Treatment
Table 2 Hemodynamic and AngiographicMeasures at Pre- and Post-Treatment
Pre-Treatment Post-Treatment p Value
Control group (n  7)
HR (beats/min) 76 2.77 83 1.88 0.098
Mean AoP (mm Hg) 71 2.74 75 3.84 0.5
LV EDP (mm Hg) 14 0.55 14 0.31 0.805
SV (ml) 19 0.81 19 0.81 0.3
CO (l/min) 1.5 0.11 1.4 0.07 0.2
LV EDV (ml) 58.7 0.7 65.4 1.7 0.006
LV ESV (ml) 40.3 0.6 48.3 1.8 0.001
LV EF (%) 31.6 1.2 27 1.3 0.002
TC (mg/dl) 206 16 201 13 0.5
Trigl (mg/dl) 53 5 46 5 0.1
Low-dose RSV (n  7)
HR (beats/min) 79 2.76 79 3.04 0.873
Mean AoP (mm Hg) 73 5.22 75 3.01 0.9
LV EDP (mm Hg) 16 0.53 15 1.06 0.407
SV (ml) 20 1.16 19 1.19 0.231
CO (l/min) 1.6 0.11 1.5 0.13 0.457
LV EDV (ml) 62.9 2.3 67.3 1.8 0.021
LV ESV (ml) 43 1.3 48 1.5 0.025
LV EF (%) 31.4 0.8 28.3 1.4 0.017
TC (mg/dl) 194 14 181 9 0.1
Trigl (mg/dl) 49 13 50 12 0.9
High-dose RSV (n  7)
HR (beats/min) 81 3.54 83 2.17 0.5
Mean AoP (mm Hg) 75 2.16 76 3.49 0.6
LV EDP (mm Hg) 15 1.13 14 0.79 0.8
SV (ml) 19 1.02 21 0.99 0.003
CO (l/min) 1.6 0.12 1.8 0.13 0.006
LV EDV (ml) 61 1.4 62 1.4 0.086
LV ESV (ml) 41.6 0.7 41.1 0.8 0.5
LV EF (%) 31.9 1.1 33.4 1.1 0.005
TC (mg/dl) 198 25 171 10 0.6
Trigl (mg/dl) 35 4 34 7 0.1
bbreviations as in Table 1.umber of circulating BMSCs compared with that in gormal dogs and a 7-fold increase compared with that in
ontrol animals (Fig. 3).
iscussion
he present study demonstrates that early, long-term
onotherapy with HD RSV prevents the progressive LV
ysfunction and remodeling in dogs with moderate HF.
his conclusion is supported by the findings that 3 months
f therapy with HD RSV increased LV EF and prevented
rogressive LV enlargement thus preventing progressive LV
lobal remodeling. The magnitude of improvement of LV
F and global remodeling was similar to that seen in this
odel after long-term therapy with the angiotensin-
onverting enzyme inhibitor enalapril (18). Furthermore,
he benefits observed with HD RSV on LV function and
emodeling were associated, at the cellular level, with a
ower VFIF, increased capillary density, improved ODD,
nd reduced cardiomyocyte hypertrophy. These positive
istomorphometric changes were also present, albeit to a
esser extent, in dogs receiving LD RSV. High-dose RSV,
ut not LD, also normalized LV tissue expression of
NF- and MMP-2. In addition, high-dose RSV induced
significant increase in the number of circulating BMSCs.
ll of these favorable observations provide strong support
or the notion that RSV, at least at high doses used in this
tudy, prevents worsening of the HF state.
ffects of RSV on LV function and global remodeling.
he observation of a preserved cardiac function and an
ttenuated LV global remodeling in dogs randomized to
D RSV is in agreement with evidence derived from
revious studies of statins in acute myocardial infarction
MI). In animal models of MI, long-term statin therapy
nitiated early after the MI was associated with increased
urvival and with improvement of systolic and diastolic LV
unction along with an attenuation of global LV remodeling
10–12). Results from clinical studies also suggest that
tatins may improve LV systolic function by attenuating the
emodeling process in patients with HF (13–15). Node et al.
13) observed a significant improvement in LV function and
reduction in LV volumes in patients with idiopathic
ilated cardiomyopathy randomized to 14 weeks of therapy
ith simvastatin compared with placebo. Recently atorva-
tatin was shown to be effective in improving the clinical
tatus of patients with nonischemic forms of HF by improv-
ng LV systolic function and decreasing LV volumes when
dded to standard optimal therapy (14,15).
nti-inflammatory effects of RSV. Long-term therapy
ith statins has also been shown to decrease circulating
lasma levels of proinflammatory cytokines (13–15) sug-
esting that statins may improve cardiac function in HF, at
east in part, by modulating the systemic inflammatory state.
umor necrosis factor- appears to play a pivotal role
mong the many proinflammatory cytokines that contribute
o the progression of HF by inducing cardiomyocyte hyper-
rophy, apoptosis, and promoting the induction of the fetal
ene program (21). Recent studies have suggested that
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August 7, 2007:551–7 Rosuvastatin in Heart FailureNF- may promote LV remodeling also by adverse
emodeling of the myocardial extracellullar matrix. De-
reased expression of TNF- results in reduced activation of
he gelatinases MMP-2 and -9, and reduced collagen
eposition and denaturation (22). These observations sup-
ort the hypothesis that inhibition of TNF- may represent
n important determinant of the statin-mediated attenua-
ion of myocardial fibrosis and hypertrophy that is ulti-
ately reflected in attenuation of global LV remodeling. In
he present study, chronic therapy with HD RSV was
ssociated with normalization of LV myocardial protein
xpression of TNF- and MMP-2.
ffects of RSV on myocardial fibrosis and cardiomyocyte
ypertrophy. Myocardial fibrosis and maladaptive extracel-
ular matrix (ECM) remodeling are common findings in the
ailing heart (23). The MMPs play a crucial role in regulating
CM turnover and, hence, myocardial structural geometry.
nhanced MMP activation in patients with HF may
ontribute to progressive LV dilation and dysfunction (23).
tatins have been shown to exert direct inhibitory effects on
MP-1 expression in human vascular endothelial cells (24)
nd to attenuate the increase in MMP-2 level in post-MI
11). Previous reports showed that selective MMP inhibi-
ion attenuates progression of LV dysfunction and remod-
Figure 1 Ventriculographic Measures of LV Function and Size
Bar graphs depicting change () in left ventricular (LV) ejection fraction (EF), LV en
post-treatment in control dogs, dogs randomized to low-dose (LD) rosuvastatin (RS
0.05 versus LD RSV.
Histomorphometric Measures
Table 3 Histomorphometric Measures
Normal
(n  6)
Contro
(n 
VFRF (%) 0.0 16.25
VFIF (%) 3.7 0.1 13.73
Cap/mm2 2,607 80 1,773
ODD (m) 8.9 0.2 11.79
MCSA (m2) 409 10 707
*p  0.05 versus normal; †p  0.05 versus control group; ‡p  0.05
2Cap/mm  capillary density; MCSA  myocyte cross-sectional area; ODD
fibrosis; VFRF  volume fraction of replacement fibrosis.ling in experimental models of HF, mainly through a
eduction of the extent of replacement and interstitial
brosis (25). In the present study, HD RSV was associated
ot only with reduced myocardial MMP-2 expression and
FIF but also with a significant decrease in MCSA, a
easure of cardiomyocyte hypertrophy. Statins have been
eported to exert antihypertrophic effects in various experi-
ental settings (26) by inhibiting the isoprenylation of
mall G-proteins such as Rac and Rho (27), and also
ngiotensin II and noradrenaline (26).
ffects of RSV on capillary density and mobilization of
MSCs. In dogs randomized to HD RSV, we observed a
ignificant increase in capillary density and in capillary-to-
ell ratio. These changes were associated with a 7-fold
ncrease in the number of circulating BMSCs compared
ith that in control animals. Statins may induce angiogen-
sis by activating the protein kinase Akt-signaling pathway
nown to promote endothelial cell survival and nitric oxide
roduction (6). Activation of the Akt pathway has also been
uggested as the mechanism underlying statin- and vascular
ndothelial growth factor-induced endothelial progenitor
ell (EPC) differentiation and mobilization from the bone
arrow (7,8). Consistent with these findings, it has been
eported that statins increase the number of EPCs and
tolic volume (EDV), and LV end-systolic volume (ESV) between pretreatment and
dogs randomized to high-dose (HD) RSV. *p  0.05 versus control group; †p 
p Low-Dose RSV
(n  7)
High-Dose RSV
(n  7)
13.21 10.7 14.22 1.94
* 12.99 0.53* 9.66 0.71*†‡
2,063 66*† 2,171 68*†
* 11.87 0.27* 10.82 0.18*†‡
559 15*† 568 12*†
low-dose rosuvastatin (RSV).d-dias
V), orl Grou
7)
1.53
0.59
62†
0.25
17*
versus
 oxygen diffusion distance; VFIF  volume fraction of interstitial
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Rosuvastatin in Heart Failure August 7, 2007:551–7nhance their proliferative and migratory activity both in
xperimental models of MI (12) and in patients with
hronic stable angina (9). Evidence is accumulating that
tatin-mediated mobilization of EPCs may be involved in
yocardial neovascularization (28). Asahara et al. (28)
howed that after permanent ligation of the left anterior
escending coronary artery in mice, bone marrow-derived
PCs are incorporated into foci of neovascularization at the
order of the infarct contributing to postnatal vasculogen-
sis. In the present study, dogs randomized to high-dose
SV showed a marked increase in the number of circulating
MSCs, the latter a recognized determinant deemed critical
or colonization and transdifferentiation of BMSCs in the
njured myocardium (29). Studies have shown that circulat-
ng BMSCs exhibited the plastic property to differentiate
nto EPCs and several cell lineages including cardiac cell
7,29,30).
Figure 2 TNF- and MMP-2
Tumor necrosis factor (TNF)- and matrix metalloproteinase (MMP)-2 protein level
of therapy with RSV. *p  0.05 versus control animals; †p  0.05 versus normal
Figure 3 Magnitude of Circulating BMSCs
Absolute number of circulating Sca-1–positive bone marrow-derived stem cells
(BMSCs). *p  0.05 versus control animals; †p  0.05 versus normal (NL).
Abbreviations as in Figure 1.iotential Clinical Implications and Conclusions
he results of the present study provide additional evidence
o sustain a biological rationale for the use of statins as an
djunctive treatment of HF in humans. The potential
herapeutic role of statins in patients with HF has thus far
een investigated in only a few small noncontrolled obser-
ational studies (14,31). A recent study suggested that
ggressive therapy with high-dose statins does not provide
he same benefits obtained with lower doses (32). These
nexpected results need to be confirmed through studies
esigned to directly compare the effects of different doses of
tatins. At present, 2 large randomized clinical trials are
nderway that examine the effects of RSV on the mortality,
orbidity, and functional status of patients with established
ymptomatic HF of both ischemic and nonischemic etiol-
gy (33,34).
In the present study, the HDs and LDs of RSV were
hosen to achieve a similar plasma concentration as seen
n humans. This, however, in and of itself, does not
nsure that the outcome seen in dogs will be the same as
hat seen in humans. Bioavailability, metabolic profile,
nd protein binding properties of RSV can differ between
ogs and humans, a fact that often makes extrapolations
mong species difficult. One thing, however, is perhaps
ore certain in that the results of the present study raise
he possibility that statins such as RSV might exert
enefits in HF that are additional to those that occur
hrough reductions in low-density lipoprotein and other
therogenic lipoproteins. Pleiotropic effects might result
rom direct effects of plasma drug on myocardial endo-
helial cells and/or cardiomyocytes and/or inflammatory
ells in the myocardium or from the changes in circulat-
sitometric units after 3 months
‡p  0.05 versus LD RSV. Abbreviations as in Figure 1.in den
 (NL); ng stem cells.
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August 7, 2007:551–7 Rosuvastatin in Heart FailureThe results of the present study indicate that early
ong-term monotherapy with HD RSV prevents progressive
V dysfunction and attenuates global and structural LV
emodeling in dogs with moderate HF. These beneficial
ffects are likely to be due, at least in part, to normalization
f TNF- and MMP-2 expression and possibly to en-
anced mobilization of BMSCs. Additional studies are
eeded to determine whether RSV or other statins have
ncremental benefit in this canine model of HF over
tandard therapy for HF such as angiotensin-converting
nzyme inhibitors and beta-blockers.
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